The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
The U.S. Supreme Court has opened the way for Hospira Inc. to introduce a generic version of Cubicin (daptomycin).The Supreme...
Daptomycin is indicated for the treatment of the following infections (see sections 4.4 and 5.1). - Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI). - Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice (see sections 4.4 and 5.1). - Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI. Daptomycin is active against Gram positive bacteria only (see section 5.1). In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
A US District Court in a case brought by Hospira has invalidated four patents extending to 2020 for Cubicin (daptomycin)from...
Pfizer Inc. and Hospira, Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire...
The EU's CHMP has recommended adopting an extension to an existing indication for Cubicin (daptomycin) from Cubist Pharma, for treating...
Hospira, Inc. has announced that the company has received 510(k) regulatory clearance from the FDA for the Plum 360 infusion...